Asher Biotherapeutics

Asher Bio’s encouraging early data against rival cancer drug sparks $108M financing

Five months after raising $55 million to back a new technology and a promising lead cancer immunotherapy, Asher Biotherapeutics has reeled in $108 million more. CEO Craig Gibbs said investors were enticed by encouraging new data suggesting Asher Bio’s lead program is superior to a competitor's.

By Frank Vinluan

Asher Bio adds $55M and takes a page from nature for cancer immunotherapy

Interluekin-2’s use as an immunotherapy has been limited by its severe side effects. Asher Bio is developing a version of IL-2 that the startup’s Chief Technology Officer Andy Yeung said could be more targeted and safer than other approaches.

By Frank Vinluan

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.